959583-52-9

Usage

Uses

Used in Chemical Research and Development:
(2S,4R)-1-(tert-butoxycarbonyl)-4-(4-fluorobenzyl)pyrrolidine-2-carboxylic acid is used as a key intermediate in the synthesis of peptides and other complex organic molecules. Its unique structure and stereospecificity make it a valuable component in the development of new chemical entities and pharmaceuticals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (2S,4R)-1-(tert-butoxycarbonyl)-4-(4-fluorobenzyl)pyrrolidine-2-carboxylic acid is used as a building block for the creation of novel drug candidates. Its specific spatial configuration and functional groups enable the design of molecules with targeted biological activities, potentially leading to the development of new therapeutic agents.
Used in Organic Synthesis:
(2S,4R)-1-(tert-butoxycarbonyl)-4-(4-fluorobenzyl)pyrrolidine-2-carboxylic acid is utilized as a versatile synthetic building block in organic synthesis. Its presence of various functional groups allows for further chemical modifications and the formation of a wide range of organic compounds with diverse applications.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1049977-93-6 (2S,4R)-4-(4-fluorobenzyl)pyrrolidine-2-carboxylic acid 
• 1356352-04-9 C₂₁H₂₈FNO₅ 
• 91229-91-3 tert-butyl (S)-N-tert-butoxycarbonylpyroglutamate 
• 35418-16-7 L-t-butyl pyroglutamate 

Downstream Products

• 1221878-02-9 (2S,4R)-1-(2-(1H-1,2,4-triazol-1-yl)acetyl)-4-(4-fluorobenzyl)-N-(4-(4-fluorophenoxy)phenyl)pyrrolidine-2-carboxamide 
• 1221878-06-3 XL₅₄₁ 
• 1221877-81-1 (2S,4R)-1-(2-(2H-1,2,3-triazol-2-yl)acetyl)-4-(4-fluorobenzyl)-N-(4-(4-fluorophenoxy)phenyl)pyrrolidine-2-carboxamide 
• 1222196-66-8 (2S,4R)-4-(4-fluorobenzyl)-N-(4-(4-fluorophenoxy)phenyl)pyrrolidine-2-carboxamide 
• 1356352-22-1 (2S,4R)-tert-butyl 4-(4-fluorobenzyl)-2-(4-(4-fluorophenoxy)phenylcarbamoyl)pyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists

A series of subtype selective sphingosine 1-phosphate receptor 1 (S1P 1) antagonists are disclosed. Our high-throughput screening campaign revealed hit 1 for which an increase in potency and mouse oral exposure was achieved with minor modifications to the chemical scaffold. In vivo efficacy revealed that at high doses compounds 12 and 15 inhibited tumor growth. Further optimization of our lead series led to the discovery of proline derivatives 37 (XL541) and 38 which had similar efficacy as our first generation analogues at significantly lower doses. Analogue 37 displayed excellent pharmacokinetics and oral exposure in multiple species.

SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS

This disclosure relates to sphingosine-1 -phosphate (SlP) receptor antagonists, compositions comprising the SlP receptor antagonists and methods for using and processes for making the SlP receptor antagonists. In particularly, this disclosure relates to sphingosine-1 -phosphate 1 (SlPl) receptor antagonists, compositions comprising the SlPl receptor antagonist and methods for using the SlPl receptor antagonist, such as in the treatment of cancer, and processes for making the SlPl receptor antagonists.